LL-37 5mg
Cathelicidin peptide — broad-spectrum antimicrobial defence
BioBlend Pharma Grade3ml vialAntimicrobial Defence
LL-37 5mg
Cathelicidin peptide — broad-spectrum antimicrobial defence
Contact for pricing
Administration
Injectable
First Results
1–2 weeks
Cycle Length
6–8 weeks
Clinical Uses
- Recurrent bacterial infection
- Biofilm resistance
- Skin and wound infections
- Adjunct immune defence
Key Benefits
- Disrupts bacterial membranes directly
- Reduces biofilm formation
- Modulates inflammation at mucosa
- Antiviral and antifungal activity
How It Works — Mechanism of Action
LL-37 is a human cathelicidin that binds negatively charged bacterial membranes to form pores, while also acting as an immune chemoattractant for neutrophils and macrophages.
Your LL-37 5mg protocol, wherever you are
A pre-filled, easy-to-carry pen for self-administration at home, the gym or the office. Dispensed safely after physician approval and delivered cold-chain to you.
Dosage Protocol
250–500 mcg subcutaneous injection daily, tapering through week 6.
When to Expect Results
Days 7–14: reduced infection frequency. Weeks 4–6: cleaner recovery markers.
Side Effects
Generally well tolerated. Rare: mild injection-site redness. Contact your physician for any unusual symptom.
Contraindications
Active cancer, pregnancy, hypersensitivity to peptide components. Always review with your physician.
Best Stacked With
Consult your physician for synergistic stacking options matched to your goal.
Understanding Your Body’s Language
Ready to start your LL-37 5mg protocol?
All peptide protocols require a physician consultation and blood work. Our licensed UAE team will craft a personalised plan for you.
Book a consultation